Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
PRAC recommends that fusafungine nose and mouth sprays are no longer marketed. Committee had concerns over serious allergic reactions and limited evidence of benefit
Notice type:
3rd Party Publications
Date:
12/02/2016
Product name or type:
Fusafungine-containing medicines
Problem Or Issue:
EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that the marketing authorisation for fusafungine-containing medicines be revoked, so the medicines can no longer be marketed in the EU. This follows a review by the PRAC which concluded that the benefits of fusafungine did not outweigh its risks, particularly the risk of serious allergic reactions. Fusafungine is an antibiotic and anti-inflamatory nose and mouth spray used to treat upper airway infections such as rhinopharyngitis (common cold).
The PRAC recommendation will be considered by the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), which will adopt a final position. HPRA will be contacting Healthcare Professionals in due course.
Background Information Or Related Documents:
PRAC Recommendation for fusafungine-containing medicines can be seen
here
Further Information:
For full EMA statement please see
here
« Back
Date Printed: 18/04/2024